Impax Laboratories (IPXL) Q2 2012 Earnings Call July 31, 2012 11:00 am ET Executives Mark Donohue - Senior Director of Investor Relations & Corporate Communications Larry Hsu - Chief Executive Officer, President and Director Bryan M. Reasons - Acting Chief Financial Officer Michael J. Nestor - Divisional President of Impax Pharmaceuticals Carole S. Ben-Maimon - President of Global Pharmaceuticals Division Analysts Shibani Malhotra - RBC Capital Markets, LLC, Research Division Corey B. Davis - Jefferies & Company, Inc., Research Division Randall Stanicky - Canaccord Genuity, Research Division Elliot Wilbur - Needham & Company, LLC, Research Division Gregory Waterman - Goldman Sachs Group Inc., Research Division Sumant S. Kulkarni - BofA Merrill Lynch, Research Division David Amsellem - Piper Jaffray Companies, Research Division Michael Kallai Tong - Wells Fargo Securities, LLC, Research Division Dewey Steadman Ken Cacciatore - Cowen and Company, LLC, Research Division Ami Fadia - UBS Investment Bank, Research Division James F. Molloy - ThinkEquity LLC, Research Division PresentationOperator
Good morning. My name is Reshaira, and I will be your conference operator today. At this time, I would like to welcome everyone to the Impax Laboratories Second Quarter 2012 Earnings Conference Call. [Operator Instructions] Thank you, Mr. Donohue, you may begin your conference. Mark Donohue Thank you. Good morning, and welcome to Impax's second quarter 2012 earnings conference call. This morning, Dr. Larry Hsu, our President and Chief Executive Officer; and Bryan Reasons, our acting Chief Financial Officer, will have some comments on our second quarter results and other business items. Following their prepared remarks, both will be available to take any questions you may have.